Filamentation induced by DTPA is associated with a decrease in Nrg1 protein level, and requires the cAMP-PKA pathway and the kinase Sok1. by Elizabeth J. Polvi (3163500)

α-TEA decreased Bcl-2 and c-FLIP (L) protein levels via caspase-8 dependent ER stress-mediated JNK/CHOP/DR5 pathway. by Richa Tiwary (363014)

A647D mutation decreases I_Na of WT and P1332L when co-expressed. by Jie Liu (15128)

Ppk1 levels are not affected by decreasing dendrite arbor size but are reduced when dendrite length increases. by Josephine W. Mitchell (17364781)

The expression of <i>Wnt1</i> gene was decreased in <i>Bmpr</i> double knockout mutants. by Lihua Qin (494786)

C/EBPε-deficient mice have decreased PMNs but develop equivalent hypoxemia and edema with VILI. by Heather D. Jones (476855)

Image_2_EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis.TIF by Santiago Castro-Zaballa (6238823)

“…Because of this fact, REM sleep is considered a natural model of psychosis. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that at sub-anesthetic dose induces psychotomimetic-like effects in humans and animals, and is employed as a pharmacological model of psychosis. …”

Image_1_EEG 40 Hz Coherence Decreases in REM Sleep and Ketamine Model of Psychosis.TIF by Santiago Castro-Zaballa (6238823)

“…Because of this fact, REM sleep is considered a natural model of psychosis. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that at sub-anesthetic dose induces psychotomimetic-like effects in humans and animals, and is employed as a pharmacological model of psychosis. …”

Tg2576 mice treated with OG showed markedly increased α-secretase cleavage of APP and significantly decreased levels of Aβ generation. by She-Qing Zhang (446556)

Supplementary Material for: Enhanced Recovery after Surgery for Radical Cystectomy Decreases Postoperative Complications at Different Times by Lannes F. (11465377)

“…Mean length of stay did not differ significantly between ERAS and non-ERAS groups (12.7 ± 6.2 and 13.1 ± 5.7 days, respectively; <i>p</i> = 0.743). …”

MeV induced <i>APOBEC3A</i> upregulation. by Pierre Khalfi (7868252)

Anti-CXCR3 group decreased number of specific CD8⁺ T cells as well as polyfunctionality after infection with <i>T</i>. <i>cruzi</i>. by Camila Pontes Ferreira (6194006)

Hyperpermeability in CV <i>sox10</i> mutants precedes decreased transit and microbial induced inflammation. by M. Kristina Hamilton (9162785)

Mean of the difference between the RV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Mean of the difference between the LV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Decreased BK responsiveness of ERK activation is found only in PS-1 FAD mutant AD fibroblasts. by Graziella Mendonsa (374346)

Decreased trabecular bone mass in 6-month-old mice lacking <i>Ceacam1</i>. by Timo Heckt (671843)

Blockade of TRPV4 inhibited the proliferation and decreased α-SMA expression in activated HSC-T6 cells. by Yang Song (88132)

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Subgroup analyses of the association between decreases in serum UA levels and poor functional outcome at 3 months. by Kuniyuki Nakamura (13040299)

“…<p>The ORs and 95% CIs of poor functional outcome (defined as an mRS score of 3–6 at 3 months) are shown according to UA decrease rate grade (G1 to G4) in each subgroup. The subgroups included (<b>A</b>) age (<75 or ≥75 years), (<b>B</b>) sex (women or men), (<b>C</b>) stroke subtype (non-cardioembolic or cardioembolic), (<b>D</b>) neurological severity (NIHSS <5 or ≥5), (<b>E</b>) CKD (presence or absence), and (<b>F</b>) UA level on admission (<292 or ≥292 μmol/L for women, <351 or ≥351 μmol/L for men). …”